Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Rheumatoid Arthritis: Update Bulletin #2 [September 2018]

Product Code:
596201001
Publication Date:
September 2018
Format:
PDF
Price:
£910

This edition presents key opinion leader (KOL) views on recent developments in the rheumatoid arthritis (RA) market. Topics covered include: Sandoz announcing the European approval of Hyrimoz, a biosimilar adalimumab, for use in all indications of the reference medicine; Mylan and Fujifilm Kyowa Kirin Biologics announcing that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Hulio, the companies' biosimilar adalimumab; Astellas’ regulatory submission seeking marketing approval of peficitinib in Japan for the treatment of RA in patients who have an inadequate response to conventional therapy; as well as Sandoz presenting data from REFLECTIONS B537-02 and EQUIRA for Zessly (biosimilar infliximab) and Erelzi (biosimilar etanercept), respectively.

Business Questions:

• How do KOLs view biosimilar adalimumab with regards to safety and efficacy?
• What do experts think of switching from one biosimilar to another biosimilar and how likely is this to occur in the future?
• According to KOLs, how can AbbVie protect Humira from biosimilar adalimumab products?
• What are KOLs’ views on peficitinib?
• What concerns do KOLs have regarding peficitinib?
• What are KOLs’ reactions to the REFLECTIONS B537-02 and EQUIRA Phase III trials for Zessly (biosimilar infliximab) and Erelzi (biosimilar etanercept), respectively.




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved